Skip to content

Author

P. Bjornstad

We have 3 of 392 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

BACKGROUND Retatrutide is an agonist of GIP, GLP-1, and glucagon receptors, and is currently under investigation for the treatment of obesity, type 2 diabetes, and other comorbidities, including knee osteoarthritis and obstructive sleep apnoea. We aimed to assess the efficacy and safety of retatrutide in adults with ob...

Virginia Bellido, C. L. le Roux, E. Ekinci et al. · 1 citation
Review Open access Sep 2026

ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome.

KEY POINTS The cardiovascular-kidney-metabolic (CKM) syndrome framework has important implications in the care of people with kidney diseases. Cardiovascular screening is important in people with kidney diseases, but the approach may differ in this high-risk population. Multiple pharmacotherapies for CKM syndrome offer...

N. Bansal, P. Bjornstad, A. Bress et al. · 3 citations
Jul 2026

Proteomic signatures of loss of glycemic control in youth-onset type 2 diabetes in the TODAY study.

Novel proteins involved in axon guidance, immune response, inflammation, and metabolism associated with LOGC in youth-onset T2D with proteins demonstrating consistent associations across the lifespan and proteomic platforms are identified.

K. Tommerdahl, Kristen R. Miller, Jian-Jun Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.